Pure Bioscience Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.101
- Today's High:
- $0.105
- Open Price:
- $0.105
- 52W Low:
- $0.07
- 52W High:
- $0.24
- Prev. Close:
- $0.11
- Volume:
- 5629
Company Statistics
- Market Cap.:
- $11.25 million
- Book Value:
- 0.011
- Revenue TTM:
- $1.69 million
- Operating Margin TTM:
- -228.22%
- Gross Profit TTM:
- $1 million
- Profit Margin:
- -246.71%
- Return on Assets TTM:
- -122.08%
- Return on Equity TTM:
- -294.86%
Company Profile
Pure Bioscience Inc had its IPO on 1996-08-08 under the ticker symbol PURE.
The company operates in the Consumer Defensive sector and Household & Personal Products industry. Pure Bioscience Inc has a staff strength of 15 employees.
Stock update
Shares of Pure Bioscience Inc opened at $0.11 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.1 - $0.11, and closed at $0.1.
This is a -8.18% slip from the previous day's closing price.
A total volume of 5,629 shares were traded at the close of the day’s session.
In the last one week, shares of Pure Bioscience Inc have slipped by -8.18%.
Pure Bioscience Inc's Key Ratios
Pure Bioscience Inc has a market cap of $11.25 million, indicating a price to book ratio of 3.8458 and a price to sales ratio of 7.9986.
In the last 12-months Pure Bioscience Inc’s revenue was $1.69 million with a gross profit of $1 million and an EBITDA of $-3697000. The EBITDA ratio measures Pure Bioscience Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Pure Bioscience Inc’s operating margin was -228.22% while its return on assets stood at -122.08% with a return of equity of -294.86%.
In Q1.3333333333333, Pure Bioscience Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 22.3%.
Pure Bioscience Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.04 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pure Bioscience Inc’s profitability.
Pure Bioscience Inc stock is trading at a EV to sales ratio of 7.292 and a EV to EBITDA ratio of -4.1296. Its price to sales ratio in the trailing 12-months stood at 7.9986.
Pure Bioscience Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.82 million
- Total Liabilities
- $569000.00
- Operating Cash Flow
- $0
- Capital Expenditure
- $39000
- Dividend Payout Ratio
- 0%
Pure Bioscience Inc ended 2024 with $1.82 million in total assets and $0 in total liabilities. Its intangible assets were valued at $1.82 million while shareholder equity stood at $1.26 million.
Pure Bioscience Inc ended 2024 with $0 in deferred long-term liabilities, $569000.00 in other current liabilities, in common stock, $-132213000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $781000.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Pure Bioscience Inc’s total current assets stands at $1.23 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $188000.00 compared to accounts payable of $432000.00 and inventory worth $149000.00.
In 2024, Pure Bioscience Inc's operating cash flow was $0 while its capital expenditure stood at $39000.
Comparatively, Pure Bioscience Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.1
- 52-Week High
- $0.24
- 52-Week Low
- $0.07
- Analyst Target Price
- $
Pure Bioscience Inc stock is currently trading at $0.1 per share. It touched a 52-week high of $0.24 and a 52-week low of $0.24. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.1 and 200-day moving average was $0.12 The short ratio stood at 2.56 indicating a short percent outstanding of 0%.
Around 4123.8% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Pure Bioscience Inc
Similar Industry Stocks (Household & Personal Products)
Most Active
Top Gainers
Top Losers
About
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.